Company Encyclopedia
View More
name
Procaps Group SA
PROC.US
Procaps Group S.A. develops, produces, and markets pharmaceutical solutions worldwide. The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision care, central nervous system, and respiratory. It also provides drugs for hospital use, such as antibiotic, blood clot, personal protective equipment, immunosuppressant, oncology, and analgesics products.
4.673 T
PROC.USMarket value -Rank by Market Cap -/-

Financial Score

23/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking120/186
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE350.20%A
    • Profit Margin12.61%B
    • Gross Margin57.77%B
  • Growth ScoreC
    • Revenue YoY-4.80%D
    • Net Profit YoY-13.15%D
    • Total Assets YoY5.81%B
    • Net Assets YoY465.78%A
  • Cash ScoreC
    • Cash Flow Margin793.24%B
    • OCF YoY-4.80%D
  • Operating ScoreB
    • Turnover0.85B
  • Debt ScoreE
    • Gearing Ratio92.29%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Procaps Group SA Appoints Fernando Moreira Muniz and Carlos Romero-Camacho as New Board Directors Amid Management Restructuring

    Procaps Group SA has appointed Fernando Moreira Muniz and Carlos Romero-Camacho as new Board Directors, effective July 14, 2025. This follows the resignations of Jose Frugone Domke and Jorddy Antonio Pérez Galindo. Romero-Camacho will join the Compensation and Nominating Committees, while Moreira Muniz will join the Audit Committee. The company published this announcement via EDGAR, and it is responsible for the information provided.

    Reuters·
    US
    PRCWF
    0.00%
    US
    PROCF
    0.00%
    US
    PROCW
    0.00%
    Reuters·
    US
    PRCWF
    0.00%
    US
    PROCF
    0.00%
    US
    PROCW
    0.00%

    Nasdaq delists Colombia’s Procaps Group due to financial shortfalls

    Nasdaq has announced the delisting of Colombia's Procaps Group due to its failure to meet financial reporting standards, effective February 4. This decision highlights the challenges businesses face in regulatory compliance. Procaps, which has seen its stock price plummet by 89% since going public, will transition to the OTC Expert Market while maintaining operational integrity. The company has appointed new interim co-CEOs and is undergoing a review of its governance. The delisting raises concerns about investor confidence and may impact funding and market relationships.

    Invezz·
    US
    PRCWF
    0.00%
    US
    PROCW
    0.00%
    US
    PROC
    0.00%
    Invezz·
    US
    PRCWF
    0.00%
    US
    PROCW
    0.00%
    US
    PROC
    0.00%

    Procaps Group Announces Leadership Change and Nasdaq Delisting

    Procaps Group has appointed Ms. Melissa Angelini and Dr. Camilo Camacho as Interim Co-CEOs following the resignation of Mr. Jose Antonio Toledo Vieira. This leadership change is unrelated to an ongoing investigation. Additionally, Procaps received a notice from Nasdaq regarding the delisting of its shares due to non-compliance with financial reporting rules, effective February 4, 2025. The shares will trade on the OTC Expert Market, which is not expected to impact business operations.

    Tip Ranks·
    US
    PROC
    0.00%
    US
    PROCF
    0.00%
    Tip Ranks·
    US
    PROC
    0.00%
    US
    PROCF
    0.00%

    Procaps Group received delisting notice from Nasdaq due to failure to file financial reports. Shares to trade on OTC as of Feb 4, 2025.

    Procaps Group, S.A. has received a delisting notice from Nasdaq due to failure to file required financial reports. As a result, its ordinary shares will begin trading on the OTC Markets Group's Expert Market starting February 4, 2025. This change impacts the trading accessibility of the company's shares for investors.

    Unusual Whales·
    US
    PROC
    0.00%
    Unusual Whales·
    US
    PROC
    0.00%

    Procaps Group Receives Delisting Notice From Nasdaq | PROC Stock News

    Procaps Group, S.A. has received a delisting notice from Nasdaq due to non-compliance with listing rules regarding financial report submissions. The company's ordinary shares will begin trading on the OTC Expert Market starting February 4, 2025. Despite the delisting, Procaps assures that its business operations and SEC reporting requirements will remain unaffected. Procaps is a prominent developer of pharmaceutical and nutraceutical solutions, operating in over 50 countries with nearly 5,000 employees.

    StockTitan·
    US
    PROC
    0.00%
    US
    PROCF
    0.00%
    StockTitan·
    US
    PROC
    0.00%
    US
    PROCF
    0.00%
    © 2025 Longbridge｜Disclaimer